Approximately 22 American military veterans die by suicide every day — a number that has remained essentially unchanged for a decade despite $13.8 billion in Veterans Affairs mental health spending since 2014. The statistic represents one of the most persistent and devastating failures in American public health, affecting a population that willingly sacrificed for the country.
The scale requires context. Veterans represent approximately 8% of the US adult population but account for 14% of adult suicides. The suicide rate among post-9/11 veterans — those who served in Iraq and Afghanistan — is particularly elevated, at 1.5x the rate for non-veterans of similar age and demographic background.
The VA mental health system faces structural challenges that billions of dollars have not resolved. Geographic barriers are significant: many veterans live in rural areas far from VA facilities. Appointment waits average 31 days for a new mental health patient. And the clinical culture of the VA — built around PTSD and combat trauma — is less equipped for the range of mental health presentations veterans experience.
Emerging evidence suggests that traditional talk therapy and antidepressants are not sufficient for treatment-resistant veteran PTSD. Psilocybin therapy, MDMA-assisted therapy for PTSD, and ketamine infusion therapy are showing striking results in veteran populations in clinical trials — but their path to VA adoption is slow.
The Mission Act, which allows veterans to receive mental health care from community providers at VA expense, has helped expand access. But community mental health providers often lack the specialized training in veteran trauma that VA clinicians have, creating quality tradeoffs.
